[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"techniques\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:techniques":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100538257","clinical-and-radiographic-evaluation-of-vital-pulpotomy-techniques-in-primary-molars-using-of-premixed-bioactive-bioceramic-mta-neo-putty-as-a-novel-pulpotomy-medication-versus-formocresol-100538257",false,"NCT06288477","Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol","Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol: A Randomized Clinical Trial.","Criteria The eligibility criteria were set according to the guidelines of AAPD, 2020. (4)\n\nInclusion Criteria:\n\n1. 4 -9 years old\n2. Primary molars with no spontaneous or provoked pain\n3. Primary molars with at least two-thirds of the root length were still present.\n4. Primary molars with no sign of internal or other kinds of root or bone resorption.\n\nExclusion Criteria:\n\n1. Patients with systemic diseases (congenital or rheumatic heart disease, hepatitis, nephritis, tumor, cyclic neutropenia, leukemia, and children on long-term corticosteroid therapy).\n2. Un-cooperative patients.\n3. Un-restorable primary molars (Grossly broken-down primary molars that have decay extending way under the gingiva and tooth with root caries).",true,"ALL","4 Years","9 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"NA","Despite the benefit of formocresol, there are toxic effects allergic reactions and local soft and hard tissue necrosis have been reported when such formaldehyde compounds were used clinically, however, the adverse effect of the clinically used of this compound are not widely reported. It has been stated that it has a side effect on the permanent successor although it results as a successful technique for the treatment of the primary teeth",[28,29,30],"Vital","Pulpotomy","Techniques","RECRUITING","2024-12-18",{"date":34,"type":35},"2024-12-20","ACTUAL",{"date":37,"type":35},"2024-03-20",{"date":39,"type":22},"2025-02-01",{"name":41,"class":42},"October University for Modern Sciences and Arts","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100569438","improving-outpatient-endometrial-biopsy-results-100569438","NCT06694246","Improving Outpatient Endometrial Biopsy Results","Outpatient Endometrial Biopsy Results; a Quality Improvement Project.","Inclusion Criteria:\n\n* All patients undergoing outpatient endometrial biopsy in the specified time interval (11\u002F2024- 4\u002F2025) will be included.\n\nExclusion Criteria:\n\n* Could not obtain the sample due to patient physicals, anxiety (patient decline), cervical stenosis, or severe bleeding","FEMALE",{"count":53,"type":22},400,"6 Months","OBSERVATIONAL","Pipelle is the most commonly used outpatient endometrial biopsy device. Pipelle endometrial biopsy can diagnose 90% of endometrial cancer cases. Pipelle endometrial biopsy is one of the first-line diagnostic procedures for women presenting with abnormal peri- and post-menopausal vaginal bleeding.\n\nInsufficient samples are obtained in 5-23% of cases. In Adan Hospital, a retrospective analysis of all outpatient endometrial samples sent to the histopathology department from April- to October 2024 study showed an insufficient sample percentage of 32% This may be attributed to factors such as patients, equipment, and physicians.\n\nThis project aims to improve the endometrial biopsy results by Identifying these factors in the Adan hospital setting, Implementing measures to modify these factors, and finally re-auditing the endometrial biopsy results after six months.",[58,59,30],"Histopathology","Screening Tool",[61,62,63,64,65,66],"Pipelle","Endometrial biopsy","histopathology","endometrial sampling","screening","outpatient","2024-12-02",{"date":69,"type":35},"2024-12-04",{"date":71,"type":35},"2024-11-01",{"date":73,"type":22},"2025-04-30",{"name":75,"class":42},"Cairo University"]